DIA-MHRA Global Summit

SESSION OVERVIEW: Scientific advances in areas such as advanced therapies, mRNA technologies, gene editing and other next generation therapeutics, are offering promise for patients. However, regulatory approval alone does not guarantee that patients will benefit from these innovations. This session will examine the journey from approval to access, exploring how regulatory decisions, health technology assessment, NHS adoption, and healthcare delivery influence whether innovative products reach the patients who need them most. The discussion will consider where barriers remain, how different stakeholders can work together more effectively, and what practical changes could help ensure that patients benefit from innovation in a timely and equitable way.

SESSION IMPACT:Attendees will explore how innovative therapies navigate the UK's approval and access landscape, gaining firsthand perspectives on the opportunities, challenges and unmet needs experienced by developers and patients alike. Through a forward-looking discussion, the session will examine whether current systems are fit for the therapies of the future and what changes are?required?to unlock innovation, accelerate patient?access?and?maximise?the potential of scientific advances to improve and save lives.